Project Experience

I have worked with Ian on a number of projects and very much enjoyed doing so. He has a strong and thorough understanding of the pharma industry from both commercial and technical angles, and has added considerable value to each opportunity we have worked on together by virtue of this

VC Dealmaker in Tech/Healthcare

Widespread commercial evaluation experience spanning multiple therapy areas for biotherapeutics and small molecules; assessments of drug opportunities in specialty care, primary care & those with orphan drug designation; biologic platforms & technologies.


To date, Atebion BDS have experience of conducting evaluations in the following areas

Atebion has conducted work in the following areas:

  • Immunology & Inflammation: RA, OA, OP, IBD, Orphan diseases; Small molecules and Biotherapeutic approaches
  • CNS: Neurodegenerative diseases, (MS, PD, AD), Pain, (Acute and chronic), Epilepsy, Migraine, Schizophrenia, Addictive disorders; Orphan diseases
  • Cardiovascular & metabolics: Anti-coagulation & thrombosis; Myotonic Dystrophy; Small molecules and biotherapeutics approaches; Orphan diseases
  • Endocrinology: Diabetes, Adrenal insufficiency; Orphan diseases
  • Infection & virology; Community and nosocomial, Gram+ve agents, Gram-ve agents; medical devices; Hepatitis C, Antivirals
  • Oncology: Solid tumours, haematological tumours, supportive care, CINV; Small molecules, mAbs, Antibody Drug Conjugates; Enabling platform technologies & discovery approaches
  • Respiratory & related: Asthma, severe asthma, COPD; Cystic Fibrosis, Bronhiectasis; Lung transplantation; Orphan Diseases; Medical devices

Atebion has provided advice and guidance on the development of - and target selection for - novel platforms for optimised drug discovery & selection
We have provided services including business development leadership & support,
Investment sourcing and Target selection & prioritisation

Atebion has advised on development path for companies with novel small molecules and biotherapeutics
We have developed plans by stage; from pre-nomination to late clinical
We have worked within mainstream & Orphan indications across multiple therapy areas, providing Target Product Profiles, market landscaping, competitor analysis and pipeline reviews

Atebion has expertise in small and large molecule development. We have provided services across multiple therapy areas for mainstream and Orphan diseases, as well as advising groups with enabling platform technologies.
We have advised companies with novel drug discovery approaches and early-stage compounds, providing drug development pathways by stage, from Pre-nomination and lead generation to late clinical development; highlighting key Investment Decision Milestones & inflexion points
Services have included product profiling, raising investment & Business Development
Within Biotherapeutics, Atebion’s projects have included antibodies, proteins & enzymes, antibody fragments & link proteins, cell line optimization platforms, Process development strategies

Atebion has provided advice, guidance, BD and investment support to companies with technologies relating to biotherapeutics and small molecules, including;

  • Novel drug discovery approaches
  • Platforms for drug re-formulation
  • Analysis, characterization and purification of proteins & mAbs
  • Drug profile optimization
  • Conjugation of Antibody Drug Conjugates

We have provided commercial feasibility assessments, investment & BD support and technology development pathways

Atebion has provided guidance on the development and marketing of smart technologies for improved disease characterisation, tools for fast & accurate patient assessment, point of care diagnostics and novel analytic technologies
We have provided commercial feasibility assessments, BD guidance & support and investment support

Atebion has provided support and guidance for a wide range of projects for Orphan diseases, including;

  • Drug and device development strategies
  • Regulatory pathway guidance
  • PreClinical & Clinical development programme plans & costings
  • Investment sourcing

We have worked on programmes across multiple therapy areas including Oncology, Immunology, Inflammation, CNS, Ophthalmic, Cardiometabolics, Endocrinology and Respiratory.
We have provided development pathways, commercialization plans & strategies, market landscaping & forecasts, S&M infrastructure & costs
We have experience of patient sub-populations for adults, paediatrics, infants & pre-terms

Atebion has worked on drug development & medical device programmes for younger populations, including new-borns, infants and paediatrics.
We have provided development pathways and offered guidance on regulatory pathways and commercialization approaches
We have provided asset development programmes & market landscaping, commercialization routes, BD & investment support for companies with novel drugs, as well as re-formulations of existing drugs for mainstream and Orphan indications

Atebion regularly provides commercialization feasibility advice for research groups with early stage assets looking to spin-out companies. We also provide ‘preparation for launch’ and launch programmes for companies looking to commercialise late-stage assets, especially within Orphan diseases.
We have worked across multiple therapy areas with small molecules (including with devices) & biotherapeutics
Atebion has provided programmes and guidance which span multiple Regions, (Europe, US, Japan, Asia Pacific) as well as for individual markets
We provide Sales & Marketing infrastructure resource and associated cost estimates, A&P programmes, PhIV development programmes, with full P&L analyses and Board presentations as required

Atebion has provided advice and guidance on compounds and technologies that have potential utility in the growing nutraceutical sector, for BioTech and Major Pharma.
We have provided commercial feasibility reports, development pathways including pricing structures across World Regions, BD support and market forecasts

Atebion offers considerable expertise in defining plans, trouble-shooting and defining process requirements for biotherapeutics including;

  • Up- and down-stream process assessments, strategies & optimization
  • Drug Product strategies
  • Drug Substance strategies
  • Small-scale analysis & characterization approaches
  • Large analytical scale purification tools and programmes
  • Cell line selection and optimsation

Atebion has provided BD and investment support to companies with early-stage assets for animal health indications, advising on development & regulatory pathways and providing relevant materials for Licensees and investors